Vanderbilt University has signed up 70 HIV-negative men who have sex with men for its part in a national HIV vaccine trial and now is looking to enroll more. Researchers have boosted their nationwide enrollment goal for the HVTN 505 trial from 1,350 to 2,200. The trial was conceived to study whether the vaccine could lower viral load in those infected; the expansion reflects scientists' desire to determine whether the vaccine can significantly reduce the number of new infections. For more information on how to volunteer, telephone 615-322-HOPE (4673) or visit www.HopeTakesAction.org.
Back to other news for November 2011